CytomX Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
CTMX$1.980.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity (Deficit)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Additional · Other · Total | ||||||
| Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders' | ||||||
| Shares | Amount | Capital | Income/(Loss) | Deficit | Equity (Deficit ) | |
| Balance at December 31, 2023 | 67,310,838 | $1 | $675,905 | $95 | $(723,448) | $(47,447) |
| Exercise of stock options and release of RSUs | 980,552 | — | 209 | — | — | 209 |
| Issuance of common stock under the Employee Stock Purchase Plan | 383,346 | — | 404 | — | — | 404 |
| Issuance of common stock under the Open Market Sale Agreement, net of issuance cost | 3,925,202 | — | 6,909 | — | — | 6,909 |
| Exercise of pre-funded warrants | 7,499,951 | — | — | — | — | — |
| Stock-based compensation | — | — | 7,668 | — | — | 7,668 |
| Other comprehensive loss | — | — | — | (68) | — | (68) |
| Net income | — | — | — | — | 31,869 | 31,869 |
| Balance at December 31, 2024 | 80,099,889 | 1 | 691,095 | 27 | (691,579) | (456) |
| Exercise of stock options and release of RSUs | 1,159,980 | — | 503 | — | — | 503 |
| Issuance of common stock under the ESPP | 207,528 | — | 308 | — | — | 308 |
| Issuance of common stock under the Open Market Sale Agreement, net of issuance cost | 4,872,861 | — | 16,262 | — | — | 16,262 |
| Issuance of common stock in follow on offering, net of issuance cost | 76,923,076 | 1 | 93,372 | — | — | 93,373 |
| Exercise of pre-funded warrants | 6,923,031 | — | — | — | — | — |
| Stock-based compensation | — | — | 6,302 | — | — | 6,302 |
| Other comprehensive income | — | — | — | 84 | — | 84 |
| Deemed dividend on warrants | — | — | 3,002 | — | (3,002) | — |
| Net loss | — | — | — | — | (17,368) | (17,368) |
| Balance at December 31, 2025 | 170,186,365 | $2 | $810,844 | $111 | $(711,949) | $99,008 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.